Global Drug-Coated Balloon Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Drug-Coated Balloon Market Overview

The global drug-coated balloon market was valued at USD 1.84 billion in 2025 and is projected to reach USD 3.97 billion by 2033, growing at a CAGR of 10.10% from 2026 to 2033. The market is witnessing steady expansion driven by the rising prevalence of peripheral and coronary artery diseases, increasing preference for minimally invasive endovascular procedures, and continuous innovation in balloon coating technologies.

The growing burden of cardiovascular diseases worldwide, coupled with an aging population and increasing risk factors such as diabetes, hypertension, and obesity, is accelerating the adoption of drug-coated balloon therapies. These devices are increasingly used as an alternative or adjunct to stenting in angioplasty procedures, particularly for in-stent restenosis and small vessel disease, offering improved long-term vessel patency and reduced need for permanent implants.

Key Market Trends & Insights

• North America dominated the global drug-coated balloon market with a 38.72% revenue share in 2025, supported by high prevalence of cardiovascular diseases, strong adoption of minimally invasive vascular procedures, and well-established catheterization lab infrastructure.
• The Paclitaxel-Based Drug-Coated Balloons segment led the market with a 68.92% share in 2025, driven by the extensive clinical adoption in peripheral and coronary interventions and strong long-term efficacy in reducing restenosis rates.
• Asia-Pacific is expected to be the fastest-growing region from 2026 to 2033, with a CAGR of 7.85%, fueled by a rapidly increasing cardiovascular disease burden, expanding healthcare access, and growing adoption of advanced endovascular treatment technologies in countries such as China and India.
• Sirolimus-Based Drug-Coated Balloons are the fastest-growing drug type, projected to register a CAGR of 8.21%, reflecting the surge in demand for safer and next-generation drug delivery technologies in vascular interventions.
• The Peripheral Artery Disease segment dominated the indication category with a 44.36% revenue share in 2025, led by increasing prevalence of lower-limb vascular blockages and rising adoption of minimally invasive endovascular therapies.
• Polymer-Based Coating accounted for 52.48% of the market, preferred by widespread use in controlled drug delivery and enhanced coating stability during angioplasty procedures.
• The Advanced Nanoparticle-Based Coatings segment is the fastest-growing technology category, with a CAGR of 8.44%, driven by increasing research focus on precision drug delivery and next-generation vascular intervention technologies.

Market Size & Forecast

• Global Market Value (2025): USD 1.84 Billion
• Expected Market Value (2033): USD 3.97 Billion
• Forecast CAGR (2026–2033): 10.10%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Global Drug-Coated Balloon Market Segmentation

Global Drug-Coated Balloon Market Trends

Trend: Rising Adoption of Drug-Coated Balloons in Peripheral Interventions

Healthcare providers are increasingly adopting drug-coated balloons for peripheral artery disease treatment due to their ability to reduce restenosis rates without leaving permanent implants inside blood vessels. The growing preference for minimally invasive vascular procedures, combined with improved balloon coating technologies and enhanced drug delivery efficiency, is strengthening adoption across hospitals and specialty cardiovascular centers. Physicians are also utilizing next-generation sirolimus-coated balloons in complex lesions and below-the-knee interventions, while ongoing clinical studies continue validating long-term efficacy and patient safety outcomes. For instance, in January 2025, Medtronic expanded clinical evaluation programs for its peripheral drug-coated balloon technologies targeting complex femoropopliteal artery disease treatment.

Global Drug-Coated Balloon Market Dynamics

Key Market Driver: Increasing Prevalence of Cardiovascular and Peripheral Artery Diseases

The rising global burden of cardiovascular diseases and peripheral artery disease is significantly increasing demand for advanced endovascular treatment solutions such as drug-coated balloons across developed and emerging healthcare markets. Aging populations, growing diabetes prevalence, obesity, smoking, and hypertension are contributing to higher incidence of vascular blockages requiring minimally invasive angioplasty procedures. Hospitals and cardiovascular centers are increasingly adopting drug-coated balloons to improve vessel patency, reduce repeat interventions, and enhance patient recovery outcomes compared with conventional balloon angioplasty techniques. For instance, in March 2024, Boston Scientific Corporation reported expanded physician adoption of its coronary and peripheral drug-coated balloon portfolio across major cardiovascular treatment centers globally.

Key Restraint/Challenge: Regulatory Scrutiny and Safety Concerns Related to Paclitaxel Devices

A major challenge in the global drug-coated balloon market is the continued regulatory scrutiny surrounding paclitaxel-coated devices and concerns regarding long-term patient safety outcomes following vascular interventions in high-risk populations. Regulatory agencies and healthcare providers continue assessing mortality data, clinical trial findings, and post-market surveillance studies associated with paclitaxel exposure in peripheral artery disease procedures. These concerns have increased compliance requirements, extended approval timelines, and created hesitation among healthcare institutions regarding broader adoption of certain drug-coated balloon technologies, particularly in emerging healthcare systems with limited reimbursement support.

For instance, in 2024, U.S. Food and Drug Administration continued post-market monitoring initiatives and safety evaluations related to paclitaxel-coated vascular intervention devices used in peripheral artery disease treatment.

Key Market Opportunity: Expansion of Sirolimus-Coated Balloon Technologies in Coronary Applications

The development of sirolimus-coated balloon technologies presents a significant market opportunity due to growing clinical interest in safer alternatives for coronary artery disease and in-stent restenosis treatment procedures globally. Advanced sirolimus delivery platforms are demonstrating promising outcomes in reducing restenosis while supporting improved vessel healing and reduced inflammatory response compared with earlier-generation drug-coated balloon products. Increasing investment in cardiovascular clinical trials, product innovation, and regulatory approvals is accelerating commercialization opportunities across hospitals, specialty cardiac centers, and emerging interventional cardiology markets worldwide. For instance, in September 2024, B. Braun SE expanded development initiatives focused on next-generation sirolimus-coated balloon platforms for complex coronary intervention procedures.

Global Drug-Coated Balloon Market Scope

The drug-coated balloon market is segmented on the basis of drug type, indication, technology, and end user.

• By Drug Type

On the basis of drug type, the global drug-coated balloon market is segmented into paclitaxel-based drug-coated balloons and sirolimus-based drug-coated balloons. The Paclitaxel-Based Drug-Coated Balloons segment dominated the market with a 68.92% share in 2025, owing to extensive clinical adoption in peripheral and coronary interventions and strong long-term efficacy in reducing restenosis rates. These balloons are widely utilized in angioplasty procedures due to their proven anti-proliferative properties and established regulatory approvals across major healthcare markets. Hospitals and cardiovascular centers continue to prefer paclitaxel-coated products because of broad physician familiarity and strong commercial availability. Continuous product innovation and improvements in drug transfer efficiency are further strengthening segment growth. The segment also benefits from rising prevalence of peripheral artery disease and increasing minimally invasive vascular procedures globally. However, ongoing regulatory scrutiny regarding long-term safety remains a key challenge for manufacturers operating in this segment.

The Sirolimus-Based Drug-Coated Balloons segment is projected to register the fastest growth at a CAGR of 8.21% from 2026 to 2033, driven by increasing demand for safer and next-generation drug delivery technologies in vascular interventions. These balloons are gaining clinical attention for their improved vessel healing characteristics and lower inflammatory response compared to traditional paclitaxel-based products. Continuous advancements in sirolimus delivery platforms and coating technologies are significantly improving therapeutic performance and treatment outcomes. Growing clinical trial activity and favorable physician perception are accelerating adoption across coronary artery disease applications. Expanding regulatory approvals and increasing investment in cardiovascular innovation are also supporting segment growth. Rising preference for advanced treatment alternatives in complex coronary lesions is expected to further drive market expansion.

• By Indication

On the basis of indication, the global drug-coated balloon market is segmented into peripheral artery disease, coronary artery disease, and other vascular diseases. The Peripheral Artery Disease segment led the market with a 44.36% share in 2025, driven by the increasing prevalence of lower-limb vascular blockages and rising adoption of minimally invasive endovascular therapies. Drug-coated balloons are widely used in femoropopliteal artery interventions due to their ability to reduce restenosis without requiring permanent implants. Increasing incidence of diabetes, obesity, and smoking-related vascular complications is significantly supporting procedure volumes globally. Hospitals and specialty cardiovascular centers are increasingly utilizing these devices to improve long-term vessel patency and reduce repeat interventions. Technological advancements in balloon coatings and catheter designs are further enhancing treatment effectiveness in PAD procedures. The segment also benefits from strong clinical evidence supporting the use of drug-coated balloons in peripheral vascular disease management.

The Coronary Artery Disease segment is expected to witness the fastest growth at a CAGR of 7.96% from 2026 to 2033, driven by rising use of drug-coated balloons in in-stent restenosis and small vessel coronary interventions. These devices are increasingly preferred in complex coronary cases where avoiding additional stent implantation is clinically beneficial. Growing awareness regarding minimally invasive coronary treatment options is accelerating physician adoption worldwide. Continuous advancements in coronary balloon technologies and improved drug delivery systems are strengthening clinical outcomes. Increasing cardiovascular disease burden and aging populations are also contributing to rising demand for coronary angioplasty procedures. Expanding clinical studies validating long-term efficacy and safety are expected to further support segment growth during the forecast period.

• By Technology

On the basis of technology, the global drug-coated balloon market is segmented into polymer-based coating, non-polymer drug coating, and advanced nanoparticle-based coatings. The Polymer-Based Coating segment dominated the market with a 52.48% share in 2025, owing to its widespread use in controlled drug delivery and enhanced coating stability during angioplasty procedures. These coatings help optimize drug transfer efficiency while ensuring adequate adhesion of therapeutic agents to balloon surfaces. Manufacturers extensively utilize polymer-based systems due to their established clinical performance and regulatory acceptance across cardiovascular applications. Continuous advancements in biocompatible polymer materials are improving product reliability and treatment outcomes. The segment also benefits from high commercial availability and broad integration across peripheral and coronary drug-coated balloon portfolios. However, concerns regarding long-term polymer residue and inflammatory reactions remain a challenge for certain clinical applications.

The Advanced Nanoparticle-Based Coatings segment is projected to register the fastest growth at a CAGR of 8.44% from 2026 to 2033, driven by increasing research focus on precision drug delivery and next-generation vascular intervention technologies. These coatings enable improved drug absorption, targeted therapeutic action, and enhanced coating durability during complex angioplasty procedures. Continuous innovation in nanotechnology and bioengineering is significantly improving balloon performance and reducing drug loss during deployment. Growing investment in cardiovascular R&D and rising clinical demand for advanced treatment efficiency are accelerating market adoption. Researchers and manufacturers are increasingly exploring nanoparticle-based systems to improve long-term vessel healing and minimize restenosis risks. Expanding commercialization of innovative cardiovascular devices is expected to further support segment growth globally.

• By End User

On the basis of end user, the global drug-coated balloon market is segmented into hospitals, cardiac catheterization laboratories, specialty clinics, and ambulatory surgical centers. The Hospitals segment accounted for the largest market share of 57.63% in 2025, driven by high patient inflow for cardiovascular procedures and the availability of advanced catheterization infrastructure. Hospitals perform a significant volume of peripheral and coronary angioplasty procedures requiring drug-coated balloon technologies for restenosis prevention and vascular treatment. Strong presence of experienced interventional cardiologists and vascular specialists further supports adoption across large healthcare institutions. Increasing investments in minimally invasive cardiovascular care and expanding access to advanced medical devices are strengthening segment growth. Hospitals also benefit from favorable reimbursement policies and integrated post-procedure patient management systems. Rising incidence of cardiovascular diseases globally continues to increase procedural demand within hospital settings.

The Ambulatory Surgical Centers segment is anticipated to witness the fastest growth at a CAGR of 7.74% from 2026 to 2033, driven by growing preference for cost-effective outpatient vascular intervention procedures. These centers provide shorter hospital stays, reduced procedural costs, and improved patient convenience compared to traditional inpatient treatment settings. Increasing advancements in minimally invasive technologies are enabling more angioplasty procedures to be safely conducted within outpatient environments. Rising healthcare cost pressures and demand for efficient treatment delivery are encouraging adoption of ambulatory care models globally. Expanding insurance coverage and supportive healthcare policies are further accelerating utilization of ASCs for cardiovascular procedures. The segment is also benefiting from increasing physician preference for specialized outpatient intervention facilities with streamlined procedural workflows.

Global Drug-Coated Balloon Market Regional Analysis

North America dominated the global drug-coated balloon market with a 38.72% revenue share in 2025, supported by high prevalence of cardiovascular diseases, strong adoption of minimally invasive vascular procedures, and well-established catheterization lab infrastructure. The region also benefits from rising prevalence of peripheral and coronary artery diseases, favorable reimbursement policies, and increasing utilization of drug-coated balloons across hospitals and catheterization laboratories for restenosis treatment applications. Continuous advancements in balloon coating technologies and growing clinical acceptance of sirolimus-based products continue to strengthen North America’s leadership position in the global market.

U.S. Drug-Coated Balloon Market Insight

The U.S. drug-coated balloon market is witnessing strong growth due to rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive vascular procedures, and continuous advancements in interventional cardiology technologies. The country’s advanced healthcare infrastructure, along with growing utilization of paclitaxel- and sirolimus-based balloon platforms, is driving demand across hospitals and catheterization laboratories. In addition, increasing focus on reducing restenosis rates and improving long-term patient outcomes is accelerating drug-coated balloon adoption across peripheral and coronary intervention procedures.

Europe Drug-Coated Balloon Market Insight

The Europe drug-coated balloon market remains a major contributor to global revenue, driven by strong clinical adoption, technological innovation, and high demand for minimally invasive cardiovascular treatment solutions. The widespread use of drug-coated balloons in peripheral artery disease and coronary artery disease procedures is supporting market expansion across the region. Increasing investments in advanced vascular intervention technologies, coupled with favorable healthcare policies and a highly developed cardiovascular care infrastructure, continue to enhance the adoption of drug-coated balloons throughout Europe.

U.K. Drug-Coated Balloon Market Insight

The U.K. drug-coated balloon market is experiencing steady growth, supported by rising adoption of minimally invasive angioplasty procedures and increasing demand for advanced cardiovascular treatment technologies. Growing investments in catheterization laboratory infrastructure and rising awareness regarding restenosis prevention solutions are contributing to market growth. Furthermore, integration of next-generation sirolimus-coated balloon technologies and increasing clinical focus on improving vascular treatment outcomes are positioning the U.K. as a key innovation hub in the drug-coated balloon industry.

Germany Drug-Coated Balloon Market Insight

The Germany drug-coated balloon market is expanding steadily due to the country’s advanced healthcare infrastructure, strong medical device manufacturing capabilities, and increasing adoption of next-generation vascular intervention technologies. Hospitals, cardiovascular centers, and research institutions are increasingly utilizing drug-coated balloons for peripheral and coronary angioplasty procedures. Continuous advancements in balloon coating technologies, drug delivery efficiency, and minimally invasive treatment approaches, along with strong government support for healthcare innovation, are further driving market growth in Germany.

Asia-Pacific Drug-Coated Balloon Market Insight

The Asia-Pacific drug-coated balloon market is expected to witness rapid growth, driven by increasing cardiovascular disease prevalence, expanding healthcare infrastructure, and rising investments in advanced vascular treatment technologies across countries such as China, India, and Japan. Growing awareness regarding minimally invasive angioplasty procedures, rising adoption of drug-coated balloon therapies, and increasing demand for cost-effective cardiovascular treatment solutions are supporting regional market expansion. In addition, the growing presence of specialized cardiac care centers and improving access to interventional cardiology procedures is accelerating drug-coated balloon adoption across healthcare institutions.

Japan Drug-Coated Balloon Market Insight

The Japan drug-coated balloon market is witnessing consistent growth due to rising investments in cardiovascular healthcare technologies, increasing aging population, and growing adoption of minimally invasive vascular intervention procedures. Hospitals, research institutes, and cardiovascular specialists are increasingly adopting advanced drug-coated balloon systems for restenosis management and peripheral artery disease treatment. Moreover, increasing integration of next-generation coating technologies and the country’s focus on improving long-term cardiovascular outcomes are further contributing to market growth.

China Drug-Coated Balloon Market Insight

The China drug-coated balloon market is growing rapidly, driven by increasing cardiovascular disease burden, expanding healthcare infrastructure, and rising government focus on improving access to advanced vascular treatment solutions. Growing adoption of minimally invasive angioplasty procedures across hospitals and cardiovascular centers is significantly boosting market demand. In addition, rising investments in medical device innovation, increasing awareness regarding peripheral artery disease treatment, and rapid advancements in interventional cardiology technologies are positioning China as one of the fastest-growing markets for drug-coated balloons globally.

Global Drug-Coated Balloon Market Share

The drug-coated balloon industry is primarily led by well-established companies, including:

• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Braun SE (Germany)
• BIOTRONIK SE & Co. KG (Germany)
• Cook (U.S.)
• Cardionovum GmbH (Germany)
• Concept Medical Inc. (India)
• Lepu Medical Technology (Beijing) Co., Ltd. (China)
• MicroPort Scientific Corporation (China)
• iVascular S.L.U. (Spain)
• Acotec Scientific Holdings Limited (China)
• Alvimedica (Türkiye)
• Balton Sp. z o.o. (Poland)
• Eurocor Tech GmbH (Germany)
• JW Medical Systems Ltd. (Israel)
• Kaneka Corporation (Japan)
• Terumo Corporation (Japan)
• OrbusNeich Medical Group Holdings Limited (Hong Kong)
• ENDOCOR GmbH (Germany)
• Translumina GmbH (Germany)

Latest Developments in Global Drug-Coated Balloon Market

• In March 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) approved its AGENT Drug-Coated Balloon, making it the first coronary drug-coated balloon approved in the United States for the treatment of coronary in-stent restenosis (ISR). The approval was supported by positive AGENT IDE clinical trial data demonstrating improved patient outcomes and reduced recurrence rates compared with conventional balloon angioplasty. This development marked a major advancement in minimally invasive coronary intervention technologies
• In March 2024, the U.S. Food and Drug Administration officially approved the AGENT Paclitaxel-Coated Balloon Catheter developed by Boston Scientific Corporation for treating coronary artery disease patients with in-stent restenosis. The device utilizes paclitaxel coating technology to help prevent arteries from narrowing again after treatment. The approval strengthened the adoption of drug-coated balloon therapies in coronary applications across the U.S. cardiovascular market
• In September 2023, MedAlliance announced that the U.S. FDA granted Breakthrough Device Designation for its SELUTION SLR drug-eluting balloon for the treatment of below-the-knee peripheral artery disease. The sirolimus-based balloon technology was developed to improve sustained drug release and reduce restenosis risks in complex vascular lesions. This designation strengthened the company’s clinical and regulatory position in the expanding peripheral intervention market
• In August 2022, B. Braun announced positive clinical study results for its SeQuent Please NEO drug-coated balloon platform in coronary artery disease treatment applications. The study highlighted improved safety and efficacy outcomes in patients undergoing angioplasty procedures for in-stent restenosis and small vessel disease. The results reinforced growing physician confidence in next-generation drug-coated balloon technologies for minimally invasive cardiovascular interventions
• In May 2021, Concept Medical announced the European launch of its MagicTouch sirolimus-coated balloon for coronary artery disease treatment following CE Mark approval. The product was developed using nanoparticle technology designed to improve targeted sirolimus delivery during angioplasty procedures. The launch represented a significant advancement in next-generation drug-coated balloon innovation and expanded treatment options for interventional cardiologists across Europe

SKU-75968